Table 1 Demographics and PET parameters at baseline

297 (100)

7.57 ± 4.41

5.49 ± 3.42

4.72 ± 5.50

3.42 ± 2.00

Age, years

0.379

0.380

0.174

0.784

 < 40

35 (11.8)

8.08 ± 4.35

5.85 ± 3.29

3.79 ± 1.97

4.04 ± 3.38

 ≥ 40

262 (88.2)

7.50 ± 4.42

5.44 ± 3.44

3.37 ± 2.01

4.81 ± 5.73

T stage

< 0.001

< 0.001

< 0.001

< 0.001

 T1

59 (19.9)

5.87 ± 3.25

3.72 ± 2.18

2.63 ± 1.41

1.40 ± 1.54

 T2

238 (80.1)

7.99 ± 4.56

5.93 ± 3.53

3.62 ± 2.08

5.55 ± 5.82

N stage

0.112

0.018

0.089

< 0.001

 N0

150 (50.5)

7.99 ± 4.69

5.95 ± 3.63

3.62 ± 2.13

5.59 ± 5.74

 N1

147 (49.5)

7.14 ± 4.07

5.02 ± 3.14

3.22 ± 1.85

3.84 ± 5.12

TNM stage

0.225

0.081

0.225

0.034

 IIA

209 (70.4)

7.39 ± 4.43

5.32 ± 3.43

3.34 ± 2.00

4.41 ± 5.28

 IIB

88 (29.6)

7.99 ± 4.35

5.89 ± 3.38

3.62 ± 2.01

5.47 ± 5.97

Pathologic prognostic stage

< 0.001

< 0.001

< 0.001

0.005

 I

167 (38.4)

6.29 ± 3.34

4.52 ± 2.46

2.87 ± 1.53

3.70 ± 4.72

 II

113 (17.8)

9.10 ± 4.98

6.55 ± 3.91

4.09 ± 2.29

5.69 ± 5.97

 III

17 (32.3)

9.98 ± 5.46

7.90 ± 4.77

4.47 ± 2.36

8.29 ± 6.98

Grade

< 0.001

< 0.001

< 0.001

< 0.001

 1

43 (14.5)

5.16 ± 2.90

3.67 ± 2.16

2.36 ± 1.33

2.33 ± 3.09

 2

110 (37)

6.21 ± 3.24

4.44 ± 2.43

2.79 ± 1.46

3.76 ± 4.94

 3

144 (48.5)

9.33 ± 4.84

6.83 ± 3.83

4.22 ± 2.21

6.17 ± 6.06

ER

< 0.001

0.001

< 0.001

< 0.001

 Positive

194 (65.3)

6.32 ± 3.36

4.55 ± 2.52

2.86 ± 1.51

3.98 ± 5.16

 Negative

103 (34.7)

9.92 ± 5.14

7.25 ± 4.14

4.48 ± 2.36

6.12 ± 5.88

PR

< 0.001

< 0.001

< 0.001

< 0.001

 Positive

178 (59.9)

6.39 ± 3.34

4.58 ± 2.47

2.91 ± 1.52

3.70 ± 4.65

 Negative

119 (40.1)

9.34 ± 5.17

6.85 ± 4.13

4.20 ± 2.36

6.25 ± 6.30

HER2

< 0.001

< 0.001

< 0.001

0.016

 Positive

55 (18.5)

9.12 ± 4.20

6.49 ± 2.96

4.29 ± 2.14

5.42 ± 5.12

 Negative

242 (81.5)

7.22 ± 4.39

5.26 ± 3.48

3.23 ± 1.92

4.56 ± 5.59

Luminal type

0.139

0.115

0.162

0.103

 Luminal A

174 (58.6)

7.44 ± 4.68

5.46 ± 3.59

3.38 ± 2.14

4.79 ± 5.75

 Luminal B

25 (8.4)

6.82 ± 3.79

4.63 ± 2.52

3.07 ± 1.63

2.69 ± 2.24

 HER2 positive

30 (10.1)

6.71 ± 2.73

4.62 ± 2.23

2.99 ± 1.11

3.50 ± 4.18

 Triple negative

68 (22.9)

8.56 ± 4.39

6.25 ± 3.57

3.85 ± 2.03

5.83 ± 5.96

Ki-67

< 0.001

< 0.001

< 0.001

0.031

 < 14%

35 (11.8)

5.19 ± 2.65

3.70 ± 1.98

2.30 ± 1.14

3.99 ± 6.54

 ≥ 14%

262 (88.2)

7.89 ± 4.50

5.73 ± 3.50

3.57 ± 2.05

4.82 ± 5.36

Hormonal therapy

< 0.001

< 0.001

< 0.001

< 0.001

 Yes

181 (60.9)

6.34 ± 3.27

4.53 ± 2.46

2.86 ± 1.45

3.71 ± 4.55

 No

116 (39.1)

9.50 ± 5.21

6.99 ± 4.11

4.30 ± 2.40

6.30 ± 6.43

HER2-targeted therapy

0.001

0.003

< 0.001

0.027

 Yes

49 (16.5)

9.17 ± 4.22

6.44 ± 2.95

4.28 ± 2.14

5.36 ± 5.12

 No

248 (83.5)

7.26 ± 4.38

5.30 ± 3.48

3.25 ± 1.93

4.60 ± 5.58

Adjuvant chemotherapy

0.128

0.051

0.178

0.012

 Yes

274 (92.3)

7.46 ± 4.37

5.37 ± 3.36

3.38 ± 1.99

4.46 ± 5.18

 No

23 (7.7)

8.91 ± 4.74

6.85 ± 3.84

3.92 ± 2.08

7.90 ± 7.98